MJ
Therapeutic Areas
Elicera Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ELC-100 (AdVince) | Neuroendocrine Tumors (NETs) | Phase I/II |
| ELC-301 | B-cell Lymphoma | Phase I/II |
| ELC-401 | Solid Tumors | Preclinical |
| ELC-201 | Solid Tumors | Preclinical |
Leadership Team at Elicera Therapeutics
JE
Jamal El-Mosleh
Chief Executive Officer, co-founder
ME
Magnus Essand
Chief Scientific Officer, Board Member, co-founder
DY
Di Yu
Chief Development Officer, co-founder
IK
Ingvar Karlsson
Chief Financial Officer
AK
Anna Koptina Gültekin
Head of Regulatory Affairs
SB
Sujata Bhoi
Senior Clinical Project Manager
AE
Agneta Edberg
Chairman of the Board
CH
Christina Herder
Board Member
SL
Sharon Longhurst
Board Member
GE
Gunilla Enblad
Advisor